BIONXT SOLUTIONS INC. Total Assets
BIONXT SOLUTIONS INC. total assets. Based on the latest financial reports, BIONXT SOLUTIONS INC. (BXT) holds total assets worth €333.75K EUR (≈ $390.19K USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is BIONXT SOLUTIONS INC. worth for the company's overall valuation and market capitalisation.
Total Assets of BIONXT SOLUTIONS INC. (2021–2025)
Total assets of BIONXT SOLUTIONS INC. from 2021 to 2025. This chart illustrates how BIONXT SOLUTIONS INC.'s total assets have evolved over time, based on quarterly financial data. See BXT live share price for real-time trading data and today's change.
BIONXT SOLUTIONS INC. - Asset Composition Analysis
BIONXT SOLUTIONS INC. Total Assets Breakdown (December 2025)
BIONXT SOLUTIONS INC. total assets breakdown as of December 2025. BIONXT SOLUTIONS INC.'s total assets of €333.75K consist of 54.6% current assets and 45.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 9.3% |
| Accounts Receivable | €79.84K | 13.5% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how BIONXT SOLUTIONS INC.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BXT working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIONXT SOLUTIONS INC.'s current assets represent 54.6% of total assets in 2025, an increase from 27.8% in 2021.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2025, down from 13.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 60.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 13.5% of total assets.
BIONXT SOLUTIONS INC. Competitors by Total Assets
Key competitors of BIONXT SOLUTIONS INC. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
BIONXT SOLUTIONS INC. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.15 | 0.04 |
| Quick Ratio | 0.01 | 0.15 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-6.51 Million | €-3.74 Million | €-7.82 Million |
BIONXT SOLUTIONS INC. - Advanced Valuation Insights
This section examines the relationship between BIONXT SOLUTIONS INC.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.68 |
| Latest Market Cap to Assets Ratio | 40.06 |
| Asset Growth Rate (YoY) | 3.9% |
| Total Assets | €591.68K |
| Market Capitalization | $23.70 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values BIONXT SOLUTIONS INC.'s assets at a significant premium (40.06x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: BIONXT SOLUTIONS INC.'s assets grew by 3.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BIONXT SOLUTIONS INC. (2021–2025)
The table below shows the annual total assets of BIONXT SOLUTIONS INC. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €591.68K ≈ $691.74K |
+3.92% |
| 2024-12-31 | €569.36K ≈ $665.64K |
-55.08% |
| 2023-12-31 | €1.27 Million ≈ $1.48 Million |
-21.40% |
| 2022-12-31 | €1.61 Million ≈ $1.89 Million |
-83.42% |
| 2021-12-31 | €9.73 Million ≈ $11.37 Million |
-- |
About BIONXT SOLUTIONS INC.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-ag… Read more